Aims: To determine factors for treatment persistence in a real-life cohort of adult neurogenic lower urinary tract dysfunction. Methods: We reviewed records of patients with neurogenic lower urinary tract dysfunction and mirabegron prescriptions. Exclusion criteria were indwelling urethral or suprapubic catheters and implanted neurostimulators. We extracted demographic data, indication for prescription, concomitant use of other agents with possible anticholinergic effect, beta blockers, duration of treatment and reason of discontinuation. Results: We included 110 subjects in this study. Neurologic diagnoses included multiple sclerosis, Parkinson’s disease, and other diagnoses (dementia, paraplegia, and tetraplegia). Previous usage of antimuscarinics was found in 78 patients (71%). Mirabegron was combined with antimuscarinics in 15 patients (14%). Drugs with any anticholinergic activity were taken by 94 subjects (86%). Mirabegron was taken for a median of 497 days and 60 patients discontinued the medication within the study period. Main reasons of discontinuation were lack of effect (44/110), side effects (10/110), and non-reimbursement (6/110). There were no differences in mirabegron discontinuation by neurological disease, beta blocker usage, or anticholinergic burden. Conclusions: Mirabegron is continued in more than half of patients with neurogenic lower urinary tract dysfunction for more than 6 months. Further research is needed to identify eventual predictive factors.

Keywords:
Multiple sclerosis, Incontinence, Neurogenic detrusor overactivity, Overactive bladder, Persistence
1.
Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD).
Neurourol Urodyn
. 2018 Mar;37(3):1152–61.
2.
Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D, et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder.
Neuroepidemiology
. 2013;41(3–4):146–55.
3.
Drake MJ, Apostolidis A, Cocci A, Emmanuel A, Gajewski JB, Harrison SC, et al. Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013.
Neurourol Urodyn
. 2016 Aug;35(6):657–65.
4.
Tijnagel MJ, Scheepe JR, Blok BF. Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.
BMC Urol
. 2017 Apr;17(1):30.
5.
Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Neurourol Urodyn
. 2014 Jan;33(1):17–30.
6.
Kamei J, Furuta A, Akiyama Y, Niimi A, Ichihara K, Fujimura T, et al. Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder.
Int J Urol
. 2015 Oct;22(10):956–61.
7.
Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
Spinal Cord
. 2016 Jan;54(1):78–82.
8.
Krhut J, Borovička V, Bílková K, Sýkora R, Míka D, Mokriš J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.
Neurourol Urodyn
. 2018 Sep;37(7):2226–33.
9.
Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
Low Urin Tract Symptoms
. 2018 May;10(2):148–52.
10.
Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
Int J Clin Pract
. 2017 Mar;71(3–4):e12824.
11.
Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada.
Can Urol Assoc J
. 2015 Sep-Oct;9(9–10):343–50.
12.
Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Eur Urol
. 2017 Sep;72(3):389–99.
13.
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application.
Aging Health
. 2008;4(3):311–20.
14.
Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review.
BMC Geriatr
. 2015 Mar;15(1):31.
15.
Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
J Urol
. 2014 Apr;191(4):1003–8.
16.
Uvin P, Boudes M, Menigoz A, Franken J, Pinto S, Gevaert T, et al. Chronic administration of anticholinergics in rats induces a shift from muscarinic to purinergic transmission in the bladder wall.
Eur Urol
. 2013 Sep;64(3):502–10.
17.
Birder L, Andersson KE. Urothelial signaling.
Physiol Rev
. 2013 Apr;93(2):653–80.
18.
Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol
. 2005 Feb;144(3):317–22.
19.
Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication.
BJU Int
. 2010 May;105(9):1276–82.
20.
Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis.
Nat Rev Urol
. 2016 May;13(5):275–88.
21.
Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum toxin A in treating neurogenic bladder.
Transl Androl Urol
. 2016 Feb;5(1):63–71.
22.
Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Eur Urol
. 2009 Mar;55(3):705–11.
23.
Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice prescription database.
Int J Clin Pract
. 2017 Oct;71(10):e12996.
24.
Peyronnet B, Castel-Lacanal E, Roumiguie M, Even L, Marque P, Soulié M, et al. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
Neurourol Urodyn
. 2017 Mar;36(3):734–9.
25.
De Ridder DJ, Muilwijk T, Weckx F, Vanden Broecke PJ, Tutolo M, Van Der Aa F. 1093 Real life discontinuation rate of botulinum toxin treatment in 100 patients with NDO.
Eur Urol Suppl
. 2015;14(2):e1093–e1093a.
26.
Joussain C, Popoff M, Phé V, Even A, Bosset PO, Pottier S, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity.
Neurourol Urodyn
. 2018 Feb;37(2):799–806.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.